We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Key miRNA Profiling to Boost Company Fortunes in 2012

By LabMedica International staff writers
Posted on 25 Jan 2012
Print article
The coming year is set to witness dramatic growth of biotechnology companies specializing in stem cell research and drug development.

One such company is Sistemic Ltd. (Glasgow, United Kingdom), which has planned a GBP 1 million investment program for 2012. A portion of this investment is to be covered by a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise.

Sistemic’s activities are currently focused on microRNAs (miRNAs) and miRNA profiling. MicroRNAs are seen as the master controllers of the cell and, as such, Sistemic believes they provide information on the effects within a whole cell or organism rather than an isolated pathway. This systems approach means that the data produced is more indicative of the biology and more informative of actual effect. As a result, Sistemic leverages miRNA based profiling/fingerprinting to provide information rich products to companies worldwide.

Systemic has developed proprietary statistical algorithms that robustly and with a high degree of confidence analyze changes to miRNAs when a cell is perturbed by a stimulus. Together with innovative visualization techniques, Systemic is able to generate a fingerprint of a key set of miRNAs known as “key miRNAs” (kmiRs) that represent these changes accurately.

The Sistemic methodology provides a rigorous yet rapid understanding of the biological changes that occur within a cell. Resulting data, allows companies to make well-informed decisions, in a timely fashion. This enables them to develop their cell (or stem cell) therapy accordingly.

Jim Reid, CEO of Sistemic said, “Securing this support from Scottish Enterprise is a major achievement and shows great support by the Scottish Government for what we are doing. It adds to an already successful year for Sistemic, a year, which has seen us grow sales dramatically and develop our customer base in Europe, USA, Japan, and Australia. We truly have become a global company during 2011 and we look forward to relocating in the first half of 2012 to allow this success and growth to continue. It is always an exciting opportunity to be on the lookout for new employees and we are ideally placed to recruit top talent. This type of grant support is crucial to help grow successful research focused biotech companies such as ours and we will ensure we make the most of it!”

Related Links:
Sistemic Ltd.

New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit
New
LH ELISA
Luteinizing Hormone ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.